Anzeige
Mehr »
Login
Dienstag, 03.12.2024 Börsentäglich über 12.000 News von 680 internationalen Medien
Eilmeldung: Goldshores aggressiver Winter-Explorationsplan nimmt Gestalt an
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 907048 | ISIN: FR0000035370 | Ticker-Symbol: 1DJ
Frankfurt
03.12.24
15:29 Uhr
20,750 Euro
-0,100
-0,48 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
BASTIDE LE CONFORT MEDICAL SA Chart 1 Jahr
5-Tage-Chart
BASTIDE LE CONFORT MEDICAL SA 5-Tage-Chart
RealtimeGeldBriefZeit
20,75021,55019:29

Aktuelle News zur BASTIDE LE CONFORT MEDICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14.11.BASTIDE: Highly dynamic organic growth in Q1 2024-25 at 9.0%: 10.9% growth in home healthcare services and rebound in the homecare business, up 6.0% / Disposal of Swiss commercial business finalized and 2024-2025 targets confirmed285Caissargues, November 14, 2024 - Groupe Bastide, a leading European provider of home healthcare services, has published its revenue for first-quarter 2024-2025, ending September 30, 2024. In...
► Artikel lesen
BASTIDE LE CONFORT MEDICAL Aktie jetzt für 0€ handeln
04.11.BASTIDE: 2024-2025 financial calendar181Caissargues, November 4, 2024 Events Dates* 2024-2025 Q1 Revenue Thursday November 14, 2024 2024-2025 H1 Revenue Thursday February 13, 2025 2024-2025 H1 Results Wednesday...
► Artikel lesen
23.10.BASTIDE: 2023-2024 annual results: Solid growth in revenue and recurring operating margin of 8.5%, exceeding the target / improved profitability and a focus on reducing debt in 2024-25212Caissargues, October 23, 2024 - Groupe Bastide, leading European provider of home healthcare services, announces its earnings for the 2023-2024 financial year ended 30 June 2024. The full-year...
► Artikel lesen
29.08.BASTIDE: Annual revenue: EUR 530 million (up 8.2%) exceeding the target of EUR 520 million / Organic growth accelerated in fourth quarter 2023-2024: up 9.5% / Profitability target of 8.4% confirmed for 2023-2024252Caissargues, August 29, 2024 In € millions 2022-2023 published 2022-2023* restated 2023-2024 published Change Fourth-quarter revenue 127.9 122.2 134.5 +10.1% Annual...
► Artikel lesen
25.07.BASTIDE: Financing resources reinforced through a new syndicated loan - Medium-term financing secured and debt maturity extended432Caissargues, July 25, 2024 Groupe Bastide announced today that it has set up a new financing contract for €375 million, including a syndicated loan and a revolving credit facility, as part of its...
► Artikel lesen
15.05.BASTIDE: Organic growth accelerated in third quarter 2023-2024 up 7.5% and sale of Homecare business in Switzerland in progress428Caissargues, May 15, 2024 In € millions 2022-2023 published 2022-2023* restated 2023-2024 published Change vs. restated 3rd quarter revenue 130.7 124.5 134.7 +8.2% 9-month...
► Artikel lesen
08.04.BASTIDE: Respiratory care therapy: Bastide wins new United Kingdom region - EUR 10 million/year contract for a minimum of seven years277Caissargues, April 8, 2024 Present in the United Kingdom home oxygen therapy market, since the acquisition of Baywater Healthcare in 2018, Bastide has announced that it has been appointed by...
► Artikel lesen
20.03.BASTIDE: 2023-2024 half-yearly results: Organic growth up 5.7%, EBITDA up 7.5%, Increase in recurring operating profit despite the inflationary context and margin of 8.3%. 2023-2024 outlook confirmed385Caissargues, March 20, 2024 In € millions - Year ended June 30 H1 2022-2023 H1 2023-2024 Change Revenue 249.7 265.0 +6.1 % EBITDA* 49.9 53.6 +7.5 % EBITDA...
► Artikel lesen
15.02.BASTIDE: Organic growth accelerated to 6.1% in second-quarter 2023-2024 and confirmation of 2023-2024 adjusted targets688Caissargues, February 15, 2024 In €m 2022-2023 2023-2024 Organic growth Published growth Q1 revenue 119.5 127.9 +5.2% +7.0% Q2 revenue 129.9 137.1 +6.1% +5.5% H1...
► Artikel lesen
9 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1